Tositumomab and iodine -131 tositumomab (Bexxar) is a new radioimmunotherapy in development for the treatment of low-grade or transformed, low-grade non-Hodgkin’s lymphoma (NHL).
O. W. Press
Advertisement
Articles by O. W. Press
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
T-DXd 5.4 mg/kg Combos Yield Fewer Grade ≥3 AEs in HER2+ Gastric Cancers
2
Sac-TMT Combo Improves PFS vs Pembrolizumab in NSCLC
3
Omitting ALND Shows Non-Inferiority, Fewer Arm-Related Complications in Breast Cancer
4
Deep Learning TME Analysis Improves Prognostic Discrimination in Stage III Colon Cancer
5